All In Biotech

Drug Trial Radar · NCT02940886

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)

A Phase III, Randomised, Open-label, Comparative Safety and Efficacy Trial of Intravenous Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®) and Iron Sucrose in Subjects With Iron Deficiency Anemia (FERWON-IDA)

Last checked: Nov 20, 2026Latest source record: Oct 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,512 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,512

Actual

Start

Nov 8, 2016

Primary completion

Mar 28, 2018

Study completion Mar 28, 2018

Sponsor

Lead sponsor
Pharmacosmos A/SIndustry
Sponsor type
Industry
First posted
Oct 21, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate safety and efficacy of iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®) compared with iron sucrose (Venofer®), in subjects diagnosed with IDA.

Conditions

  • Iron Deficiency Anaemia
  • Iron Deficiency Anemia

Interventions

  • Iron isomaltoside/ferric derisomaltoseDrug

    Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial. The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride (100 mL bags) and administered as a single IV infusion over approximately 20 minutes.

  • Iron sucroseDrug

    Iron sucrose (Venofer®; 20 mg elemental iron/mL) was the comparator in this trial. Iron sucrose was administered as 200 mg undiluted IV injections over approximately 2-5 minutes and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline. A cumulative dose of 1000 mg was recommended.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Hemoglobin (Hb) From Baseline to Week 8Time frame: Baseline to week 8
  2. Incidence of Protocol-defined Serious or Severe Hypersensitivity ReactionsTime frame: Baseline to week 8

Locations

114 sites in 1 country. Site status is shown where the registry gives one.

  • Pharmacosmos Investigational Site

    Birmingham, Alabama

  • Pharmacosmos Investigational Site

    Dothan, Alabama

  • Pharmacosmos Investigational Site

    Guntersville, Alabama

  • Pharmacosmos Investigational Site

    Phoenix, Arizona

  • Pharmacosmos Investigational Site

    Little Rock, Arkansas

  • Pharmacosmos Investigational Site

    Little Rock, Arkansas

  • Pharmacosmos Investigational Site

    Foothill Ranch, California

  • Pharmacosmos Investigational Site 1

    La Mesa, California

  • Pharmacosmos Investigational Site 2

    La Mesa, California

  • Pharmacosmos Investigational Site

    Long Beach, California

  • Pharmacosmos Investigational Site

    National City, California

  • Pharmacosmos Investigational Site 1

    Northridge, California

  • Pharmacosmos Investigational Site 2

    Northridge, California

  • Pharmacosmos Investigational Site

    Oceanside, California

  • Pharmacosmos Investigational Site

    Quartz Hill, California

  • Pharmacosmos Investigational Site

    Rialto, California

  • Pharmacosmos Investigational Site

    Riverside, California

  • Pharmacosmos Investigational Site

    San Diego, California

  • Pharmacosmos Investigational Site

    San Diego, California

  • Pharmacosmos Investigational Site

    San Marcos, California

  • Pharmacosmos Investigational Site

    Whittier, California

  • Pharmacosmos Investigational Site

    Plainville, Connecticut

  • Pharmacosmos Investigational Site

    Aventura, Florida

  • Pharmacosmos Investigational Site

    Boynton Beach, Florida

  • Pharmacosmos Investigational Site 1

    Doral, Florida

  • Pharmacosmos Investigational Site 2

    Doral, Florida

  • Pharmacosmos Investigational Site

    Doral, Florida

  • Pharmacosmos Investigational Site

    Fort Lauderdale, Florida

  • Pharmacosmos Investigational Site

    Hialeah, Florida

  • Pharmacosmos Investigational Site

    Hialeah, Florida

  • Pharmacosmos Investigational Site

    Hialeah, Florida

  • Pharmacosmos Investigational Site

    Hollywood, Florida

  • Pharmacosmos Investigational Site

    Jacksonville, Florida

  • Pharmacosmos Investigational Site

    Kissimmee, Florida

  • Pharmacosmos Investigational Site

    Lake City, Florida

  • Pharmacosmos Investigational Site

    Lake Worth, Florida

  • Pharmacosmos Investigational Site

    Lake Worth, Florida

  • Pharmacosmos Investigational Site

    Miami, Florida

  • Pharmacosmos Investigational Site

    Miami, Florida

  • Pharmacosmos Investigational Site

    Miami, Florida

Showing 40 of 114 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.